Markus Eckstein (@Markuseckstein3) “Do we understand PDAC? These tumors have a particular desmoplastic stroma, are h”

2026.07.02 13:33

Do we understand PDAC? These tumors have a particular desmoplastic stroma, are hypovascularized, and exhibit proven high osmotic pressure in their stroma. As indicated by the 0% ORR achieved by T-DXd in 2/3+ PDACs and the lack of additive value from zolbetuximab (also an antibody), this cannot be explained solely by chemoresistance. Anti-PD-1 antibodies were also inactive. There is no strong evidence for this, but antibodies probably cannot reach PDAC tumor cells. This is underscored by the 0% ORR to T-DXd, while some patients respond to small-molecule chemotherapy. How can we overcome this? Potentially with next-generation small peptide compounds or direct tumor stroma remodeling.

显示更多

Arndt Vogel@ArndtVogel

2026.07.02 13:09

Zolbetuximab plus gemcitabine and nab-paclitaxel in CLDN18.2+ metastatic PDAC: phase II GLEAM study @ESMO-GI 👉Primary endpoint not met, no OS & PFS benefit 👉Toxicity manageable 🧐Not the right drug, but maybe the right target

显示更多